Miscellaneous (e.g., Subcellular Parts Of Micro-organisms, Etc.) Patents (Class 435/317.1)
-
Patent number: 12209256Abstract: Recombinant phages that infect and kill bacterial hosts in response to user-defined inputs are provided. The components that encode the user-defined inputs can be combined, such that multiple inputs are maintained on a single recombinant phage, enabling precise control over the targeting strategy. The phages can be engineered to kill a specific bacterial species or multiple species simultaneously. Recombinant phages can also be engineered to harbor fluorescent and bioluminescent reporter genes that enable them to be used for tracking, detection, and in biosensing applications. Recombinant phages can also be used to lyse bacterial cells that produce recombinant proteins, as a rapid method to enable extraction and high-level purification of potentially valuable and/or industrially important proteins. Systems are provided that can be used to control the activity of a protein of interest, by taking advantage of an interaction between Qtip and a phage repressor protein.Type: GrantFiled: October 31, 2019Date of Patent: January 28, 2025Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Justin E. Silpe, Bonnie L. Bassler
-
Patent number: 12128128Abstract: In one aspect, a composition for topical application is provided. The composition comprises a base. Dispersed within the base is elemental silver as a colloidal suspension, and plant extract from at least 6 plants. The plants are selected from the group consisting of Echinacea purpurea, Stellaria media, Aloe vera, Matricaria recutita, Hypericum perforatum, Calendula officinalis, Equisetum arvense, Symphytum officinale, Panax ginseng, Rumex crispus, Arctium lappa, Trifolium pratense, Chelidonium majus, Thuja occidentalis, Urtica dioica, Mahonia aquifolium, and Galium aparine.Type: GrantFiled: March 29, 2018Date of Patent: October 29, 2024Assignee: Phyto Sophos Ltd.Inventor: Laura Dewar
-
Patent number: 11976337Abstract: This disclosure concerns amplification primers, hybridization assay probes, compositions containing such primers and probes, and associated reagents, kits, and methods, that can be used to analyze samples for the presence of Influenza A virus, Influenza B virus, Respiratory Syncytial Virus A, and/or Respiratory Syncytial Virus B target nucleic acids.Type: GrantFiled: March 23, 2018Date of Patent: May 7, 2024Assignee: GEN-PROBE INCORPORATEDInventors: Matthias Jost, Pamela Douglass, Daniel P. Kolk, Mehrdad R. Majlessi
-
Patent number: 11952566Abstract: The invention relates to an apparatus 10 for storing and/or processing at least one medium 11, in particular a bioprocessing device, comprising at least one disposable container 1, which is designed to accommodate at least some of the at least one medium 11, and at least one overpressure protection means 5, which is fluid-connected to the at least one disposable container 1. The at least one overpressure protection means is designed, when triggered, to conduct at least some of the at least one medium 11 into an apparatus region 3a? in front of the overpressure protection means 5 in relation to a flow direction F, in particular into the at least one disposable container 1 and/or into at least one further, second container 1a.Type: GrantFiled: January 4, 2019Date of Patent: April 9, 2024Assignee: Sartorius Stedim Biotech GmbHInventors: Bernhard Diel, Andreas Klemm, Matthias Hielscher, Alexandre Espachs, André Grebe
-
Patent number: 11845963Abstract: Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.Type: GrantFiled: January 19, 2018Date of Patent: December 19, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Noura S. Abul-Husn, Omri Gottesman, Alexander Li, Xiping Cheng, Yurong Xin, Jesper Gromada, Frederick E. Dewey, Aris Baras, Alan Shuldiner
-
Patent number: 11845056Abstract: A peptide synthesis instrument can be used for small scale peptide synthesis. The instrument can include several unique features, including a compression style reaction vessel permitting quick setup of the reaction vessel, a double reaction vessel system permitting efficient mixing without loss of solvent or solvent-to-resin contact, gravity-fed heated reservoirs establishing a fixed volume for delivery to the reaction vessel, fume-free solvent addition permitting solvent addition to fixed bottles, and an improved amino acid manifold assembly which reduces the number of components and increases the ease of use of the instrument. Each of these features improve upon the current state of the art in solid phase automated peptide synthesizers.Type: GrantFiled: November 15, 2022Date of Patent: December 19, 2023Assignee: CSBIO INSTRUMENTATION CO.Inventors: Dario Slavazza, Yoheng Chang, David Lippoth
-
Patent number: 11730768Abstract: The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.Type: GrantFiled: October 30, 2019Date of Patent: August 22, 2023Assignee: UNIVERSITY OF MIAMIInventors: Evangelos V. Badiavas, Arsalan Q. Shabbir, Stephen C. Davis
-
Patent number: 11702671Abstract: An expression vector containing appropriate mitochondrion-targeting sequences (MTS) and appropriate 3?UTR sequences provides efficient and stable delivery of a mRNA encoding a protein (CDS) to the mitochondrion of a mammalian cell. The MTS and 3?UTR sequences guide the CDS mRNA from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the CDS is translated. This provides an efficient translocation of a mature functional protein into the mitochondria. A method of targeting mRNA expressed in the nuclear compartment of a mammalian cell to the mitochondrion is also provided. The vector and methods can be used to treat defects in mitochondrial function.Type: GrantFiled: May 26, 2021Date of Patent: July 18, 2023Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Marisol Corral-Debrinski, Jose-Alain Sahel, Valerie Kaltimbacher, Crystel Bonnet
-
Patent number: 11666882Abstract: Flow control mechanisms control the direction and flow rate of synthesis reagent through one or more synthesis reaction vessels for automated solid phase synthesis. Selectable, known, and reproducible positive or negative pressure differentials (?5 to +10 psi) accomplish controlled, bidirectional (forward and reverse) flow of synthesis reagents through synthesis media contained within the reaction vessels. Venturi-based vacuum apparatus, valves, electronic pressure regulators and compound digital pressure gauge, can be added to automated solid phase synthesis instruments to provide, control, and monitor known, selectable, reproducible negative and positive pressures to one or both valve sealable and un-sealable ends (inlets and outlets) of the reaction vessel as needed to generate and reverse said pressure differentials between the opposite ends of said synthesis reaction vessels, yielding controlled forward and backward flows of synthesis reagents through the synthesis media.Type: GrantFiled: June 25, 2021Date of Patent: June 6, 2023Assignee: Biolytic Lab Performance, Inc.Inventors: Thomas J. Demmitt, Laurent Jaquinod
-
Patent number: 11649482Abstract: The present disclosure relates to compositions and methods for performing droplet-based high throughput sequencing upon genomic DNA of single cells (e.g., individual sperm). The instant disclosure provides a droplet that includes: i) a mammalian cell nucleus; and ii) a microbead presenting attached oligonucleotides, where the attached oligonucleotides include a nucleic acid sequence capable of hybridization and capture of genomic DNA and a microbead identification sequence that is common to all oligonucleotides attached to the microbead, where the mammalian cell nucleus is accessible to the microbead-attached oligonucleotides to an extent sufficient to allow for genomic DNA capture and amplification of genomic DNA to occur within the droplet.Type: GrantFiled: April 26, 2019Date of Patent: May 16, 2023Assignee: President and Fellows of Harvard CollegeInventors: Avery Davis Bell, Steven A. McCarroll
-
Patent number: 11643646Abstract: The present invention provides a method and a system for the isolation and purification of nucleic acids from nucleic acid-containing material using a modified porous material containing cationic groups in a solid-liquid phase system. In some embodiments, the present invention is capable of obtaining nucleic acids with sufficient purity and quantity in a relatively simple way to enable accurate subsequent analysis or processing. In some embodiments, the liquid phase comprises an aqueous two-phase system (ATPS), comprising a first phase and a second phase, and the solid phase comprises a porous material, wherein the two phases travel through the porous material. In some embodiments, the nucleic acids enter the pores of the porous material and subsequently travel through the porous material while preferentially partitioning into one of the phases.Type: GrantFiled: January 18, 2019Date of Patent: May 9, 2023Assignee: PHASE SCIENTIFIC INTERNATIONAL, LTD.Inventor: Yin To Chiu
-
Patent number: 11619637Abstract: The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.Type: GrantFiled: March 26, 2018Date of Patent: April 4, 2023Assignee: NanoSomiX, Inc.Inventor: Edward J. Goetzl
-
Patent number: 11529370Abstract: A composition for strengthening skin barrier or improving skin barrier function is able to improve objective indicators related to the protection of skin barrier, the strengthening of skin barrier, and/or the improvement of skin barrier function. The composition exhibits the effects of increasing the amount of ceramides, dihydroceramides and sphingoid bases, increasing the activities of enzymes that are involved in the synthesis thereof, and decreasing the activities of enzymes that are involved in the degradation thereof. In addition, the composition is able to restore skin barrier function by reducing TSLP, IL-4, and IL-13 which are closely associated with skin barrier damage, and thus interrupting a vicious circle in which the lipids and proteins contributing to skin barrier decrease.Type: GrantFiled: May 20, 2020Date of Patent: December 20, 2022Assignee: ExoCoBio Inc.Inventors: Yong Weon Yi, Byong Seung Cho
-
Patent number: 10584363Abstract: Methods of producing single-stranded deoxyribonucleic acids (ssDNAs) are provided. Aspects of the methods include generating a double stranded deoxyribonucleic acid (dsDNA) and then selectively degrading one strand of the dsDNA to produce a ssDNA. ssDNAs produced using methods of the invention find use in a variety of applications, including genomic modification applications. Also provided are compositions, e.g., kits, that find use in practicing various embodiments of the invention.Type: GrantFiled: June 2, 2017Date of Patent: March 10, 2020Assignee: Takara Bio USA, Inc.Inventors: Hiroyuki Matsumoto, Michael Haugwitz, Andrew Farmer, Magnolia Bostick
-
Patent number: 10455783Abstract: The present invention relates to breeding methods to enhance the germplasm of a plant. The methods describe the identification and accumulation of preferred haplotype genomic regions in the germplasm of breeding populations of maize (Zea mays) and soybean (Glycine max). The invention also relates to maize and soybean plants comprising preferred haplotypes.Type: GrantFiled: April 5, 2012Date of Patent: October 29, 2019Assignee: Monsanto Technology LLCInventors: Jason Bull, David Butruille, Sam Eathington, Marlin Edwards, Anju Gupta, G. Richard Johnson, Robert Stefan Reiter
-
Patent number: 10416161Abstract: A method for diagnosing hepatitis virus infection or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers present on exosomes in a bodily fluid sample from the subject is disclosed. Also disclosed are a method for monitoring the course of a hepatitis virus infection or a hepatitis disease condition in a subject and a method for monitoring effectiveness of treatment to a subject with an anti-hepatitis virus agent based on hepatitis virus-associated biomarkers present on exosomes in bodily fluid samples from the subject, as well as a kit for diagnosing hepatitis virus infection and/or a hepatitis disease condition in a subject based on hepatitis virus-associated biomarkers on exosomes in bodily fluid samples from the subject.Type: GrantFiled: September 20, 2016Date of Patent: September 17, 2019Assignee: MOREHOUSE SCHOOL OF MEDICINEInventors: Gale W. Newman, Sam Anyanwu
-
Patent number: 10036007Abstract: Proposed is a method of easily finding an error during analysis of various library sequences of nucleic acid base sequences after synthesizing a gene library using a combination of three nucleic acid base sequences (codon) translated into the same protein. This shows that it is possible to create a gene library having the same protein sequence but different nucleic acid base sequences. The present disclosure provides a novel experimental method capable of measuring a correlation between gene expression according to change in a codon by changing the usage of a codon optimized to express a specific gene in vivo.Type: GrantFiled: December 11, 2013Date of Patent: July 31, 2018Assignee: CELEMICS, INC.Inventors: Duhee Bang, Sangun Park, Joongoo Lee, Jeewon Lee
-
Patent number: 10034921Abstract: In one aspect, the disclosure provides proteins with modified glycosylation and methods of their production. In aspect, the disclosure provides transgenic animals and cells for the production of proteins with modified glycosylation. In some embodiment, the modified glycosylation is increased sialylation.Type: GrantFiled: February 13, 2014Date of Patent: July 31, 2018Assignee: Laboratoire Français du Fractionnement et des BiotechnologiesInventors: Li-How Chen, Harry M. Meade
-
System and method for production of on-demand proteins in a portable unit for point of care delivery
Patent number: 9982227Abstract: A portable and mobile bioprocessing system and method for protein manufacturing that is compact, integrated and suited for on-demand production of any type of proteins and for delivery of the produced proteins to patients or for assay purposes. The portable system and method can also be used for efficient on-demand production of any type of protein with point-of-care delivery.Type: GrantFiled: April 11, 2016Date of Patent: May 29, 2018Assignee: University of Maryland, Baltimore CountyInventors: Govind Rao, Yordan Kostov, Leah Tolosa, Xudong Ge, Douglas Frey -
Patent number: 9865827Abstract: Embodiments of apparatus, compositions, methods, systems, and articles of manufacture are disclosed relating to the optimization and production of biological components for use in biohybrid photosensitive devices and systems and other applications. In some embodiments, biologically derived components are disclosed having properties and/or characteristics that are optimized for applications of interest relative to corresponding components derived from naturally occurring organisms. In some embodiments, properties and/or characteristics of biological components are optimized by subjecting organisms and/or populations thereof to forced adaptation.Type: GrantFiled: May 18, 2015Date of Patent: January 9, 2018Inventors: Jeffrey T. LaBelle, Vincent B. Pizziconi
-
Patent number: 9839207Abstract: The present invention relates to a HSP27 mutation (S135F) mediated Charcot-Marie-Tooth disease (CMT) animal model. Particularly, the vector expressing mutant HSP27 protein wherein the 135th serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected. The selected mouse was confirmed to display Charcot-Marie-Tooth disease phenotype, so that the animal model was expected to be efficiently used for the evaluation of the effect of Charcot-Marie-Tooth disease treating material candidates.Type: GrantFiled: October 1, 2015Date of Patent: December 12, 2017Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, CHONG KUN DANG PHARMACEUTICAL CORPInventors: Yun Tae Kim, Byung-Ok Choi, Sung Chul Jung, Young Bin Hong, So-Youn Woo, Jin-Mo Park
-
Patent number: 9510570Abstract: The present invention provides a CD81 and OCLN double transgenic mouse and its construction method and use. The double transgenic mouse can be used to constitute acute and chronic HCV infection in a mouse model.Type: GrantFiled: June 24, 2014Date of Patent: December 6, 2016Assignee: Wuhan Institute of Virology, CASInventors: Hong Tang, Xin-Wen Chen, Ji-Zheng Chen, Yang Zhao, Chao Zhang, Hai-Rong Chen
-
Publication number: 20150150160Abstract: The present invention relates to methods to modify at least one target locus in a plant cell, comprising, providing a plant cell with one or more target loci and one or more donor loci, followed by induction of homologous recombination between homologous regions of at least one target locus and at least one donor locus by at least one rare cleaving nuclease. The present invention related also to target loci, donor loci and nuclease loci used in these methods, and plant cells, plants and plant parts comprising these target loci, donor loci, nuclease loci and/or the recombined loci.Type: ApplicationFiled: January 4, 2013Publication date: May 28, 2015Inventors: Rocio Sanchez-Fernandez, Christian Biesgen, Holger Puchta, Nadine Roth, Friedrich Fauser, Michael Pacher
-
Publication number: 20150135358Abstract: Transgenic seed for crops with enhanced agronomic traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more enhanced traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein.Type: ApplicationFiled: October 24, 2014Publication date: May 14, 2015Inventors: Maria C. Bohannon, Marie Coffin, Amanda Winslow, Faten Shaikh
-
Publication number: 20150118263Abstract: The present application relates to glycoengineered outer membrane vesicles obtained from recombinant, gram-negaetive bacteria comprising hetereologous DNA encoding an enzyme or enzymes that produce a heterologous glycan that replaces all or a portion of the naturally-occurring O antigen in the lipopolysaccharides of the bacteria. Also provided by the present application are immunogenic compositions and vaccines prepared from the glycoengineered outer membrane vesicles expressing the heterologous glycans at their surface.Type: ApplicationFiled: April 26, 2013Publication date: April 30, 2015Applicant: The Governors of the University of AlbertaInventors: Mario Feldman, Nancy Price, Fatima Garcia-Quintanilla, Maria Veronica Ielmini
-
Publication number: 20150110826Abstract: The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same.Type: ApplicationFiled: October 17, 2014Publication date: April 23, 2015Applicant: SANOFI VACCINE TECHNOLOGIES, S.A.S.Inventors: Anne-Cecile V. BAYNE, James Casey LIPPMEIER, Kirk Emil APT, Ross Eric ZIRKLE
-
Publication number: 20150093820Abstract: A method of recovering a target from a sample is provided. The method comprises the adding a substrate coupled binding element to the sample comprising the target to form a substrate coupled binding element-target complex; precipitating the complex by changing one or more environmental conditions of the substrate and recovering the target and the substrate coupled binding-element under mild conditions.Type: ApplicationFiled: October 2, 2013Publication date: April 2, 2015Applicant: General Electric CompanyInventors: Anthony John Murray, Radislav Alexandrovich Potyrailo, Andrew David Pris, Nandini Nagraj
-
Publication number: 20150093819Abstract: The invention relates to a bioreactor system characterized by its capacity in cultivating cells in all three states: static, dynamic, or alternating between static and dynamic states in the same cell culture container or containers, with the even distribution of cells in cell static culture following a dynamic culture. In the invented bioreactor system, the combined application of the magnetically controlled agitation and the cell culture container inversion as well as the combined application of the vertical rotating culture and horizontal static culture are the two strategies in building ideal bioreactors for the cell culture alternating between static and dynamic states in the same cell culture container, which can minimize the sheer-stress and provide cells an ideal metabolic environment.Type: ApplicationFiled: September 29, 2013Publication date: April 2, 2015Inventor: Yongxin Zhang
-
Publication number: 20150064751Abstract: The embodiments described herein pertain to cells, and methods for preparing cells, that can be used as biocatalysts by altering enzymes that compete for a substrate or product of a pathway of interest such that the targeted enzyme is sensitive to a site-specific protease, which protease is expressed but relocated in the cell to a site where it is not in contact with the targeted enzyme in the intact cell. Upon cell lysis, the protease contacts the target enzyme, which is then inactivated by protease cleavage.Type: ApplicationFiled: November 14, 2014Publication date: March 5, 2015Applicants: The Board of Trustees of the Leland Stanford Junior University, GreenLight Biosciences, Inc.Inventor: James R. Swartz
-
Patent number: 8969653Abstract: The present application relates to extracellular vesicles (EVs) derived from gram-positive bacteria. In detail, the present application provides animal models of disease using extracellular vesicles derived from gram-positive bacteria, provides a method for screening an active candidate substance which is capable of preventing or treating diseases through the animal models of disease, provides vaccines for preventing or treating diseases caused by extracellular vesicles derived from gram-positive bacteria, and provides a method for diagnosing the causative factors of diseases caused by gram-positive bacteria using extracellular vesicles.Type: GrantFiled: August 26, 2010Date of Patent: March 3, 2015Assignee: Aeon Medix Inc.Inventors: Yong Song Gho, Yoon Keun Kim, Eun Young Lee, Sung Wook Hong, Ji Hyun Kim, Seng Jin Choi
-
Publication number: 20150047074Abstract: In one aspect, a composition can include an organelle, and a nanoparticle having a zeta potential of less than ?10 mV or greater than 10 mV contained within the organelle. In a preferred embodiment, the organelle can be a chloroplast and the nanoparticle can be a single-walled carbon nanotube associated with a strongly anionic or strongly cationic polymer.Type: ApplicationFiled: August 7, 2014Publication date: February 12, 2015Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Michael S. Strano, Juan Pablo Giraldo Gomez, Sean Mitchell Faltermeier, Markita P. Landry
-
Publication number: 20150026840Abstract: To produce a bacterial microcompartment shell, or a designed shell based on naturally occurring bacterial microcompartment shells in a new host organism, a synthetic operon is constructed that contains the desired shell protein genes and translation efficiency is controlled by host specific ribosomal binding sites. Proteins or other molecules can be encapsulated in the microcompartment shells by various methods described herein. The constructs can also be used to express self-assembling sheets comprised of shell proteins.Type: ApplicationFiled: March 14, 2014Publication date: January 22, 2015Applicant: The Regents of the University of CaliforniaInventors: Cheryl A. Kerfeld, Jonathan K. Lassila, James N. Kinney
-
Publication number: 20150025157Abstract: There is provided a novel gelator containing a sugar derivative. A gelator including a compound of Formula (1) or Formula (2): wherein each of R1 and R3 is independently a linear or branched alkyl group having a carbon atom number of 1 to 20, a cyclic C3-20 alkyl group, or a linear or branched alkenyl group having a carbon atom number of 2 to 20, n is 0 or an integer of 1 to 4, R2 is a hydrogen atom, a linear or branched alkyl group having a carbon atom number of 1 to 10, or an aryl group optionally having a substituent, and R4 and R5 are each a hydroxy group.Type: ApplicationFiled: March 8, 2013Publication date: January 22, 2015Inventors: Fumiyasu Ono, Seiji Shinkai, Osamu Hirata
-
Patent number: 8936666Abstract: A noble metal adsorption agent includes algae or residue of algae having an amino group as a functional group. A noble metal is retrieved by a method including: adsorbing the noble metal on the noble metal adsorption agent; and retrieving the noble metal. The noble metal is solved in a liquid. Thus, by using the noble metal adsorption agent, the noble metal is selectively retrieved.Type: GrantFiled: June 20, 2011Date of Patent: January 20, 2015Assignees: Denso Corporation, Saga UniversityInventors: Hisaya Kato, Toshiyuki Morishita, Kinya Atsumi, Minoru Kurata, Katsutoshi Inoue, Hidetaka Kawakita, Keisuke Ohto
-
Patent number: 8936935Abstract: The present invention relates to a population of monodisperse magnetic nanoparticles with a diameter between 1 and 100 nm which are coated with a layer with hydrophilic end groups. Herein the layer with hydrophilic end groups comprises an inner layer of monosaturated and/or monounsaturated fatty acids bound to said nanoparticles and bound to said fatty acids, an outer layer of a phospholipid conjugated to a monomethoxy polyethyleneglycol (PEG) comprising a hydrophilic end group, or comprises a covalently bound hydrophilic layer bound to said nanoparticles.Type: GrantFiled: May 19, 2011Date of Patent: January 20, 2015Assignees: IMEC, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Deepak Balaji Thimiri Govinda Raj, Liesbet Lagae, Wim Annaert, Gustaaf Borghs
-
Patent number: 8927251Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.Type: GrantFiled: August 30, 2006Date of Patent: January 6, 2015Assignee: The University of ChicagoInventors: Guoying Zhou, Bernard Roizman
-
Publication number: 20140356943Abstract: The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free.Type: ApplicationFiled: February 25, 2014Publication date: December 4, 2014Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Philippe Mangeot, Vincent Lotteau, Marc Peschanski, Mathilde Girard
-
Publication number: 20140357521Abstract: The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.Type: ApplicationFiled: January 21, 2013Publication date: December 4, 2014Inventors: Jan Steyaert, Nico Callewaert, Toon Laeremans, Els Pardon, Kristof Vandewalle, Katrien Claes
-
Publication number: 20140349338Abstract: The present invention relates to novel bacteria and the uses thereof. The invention particularly relates to bacteria having a metabolic pathway ratio between Pentose phosphate and glycolysis greater than 0.5, and their uses in the chemical, pharmaceutical or agro-chemical industries, e.g., for producing compounds of industrial interest.Type: ApplicationFiled: December 21, 2012Publication date: November 27, 2014Applicant: DEINOVEInventors: Jean-Paul Leonetti, Juha-Pekka Pitkanen, Paula Jouhten
-
Publication number: 20140329325Abstract: A device for use in laser optical transfection of biological targets including an optofluidic microdevice and a piece of optical glass. The optofluidic microdevice has a central vertical outlet and a microchannel network that includes a plurality of entrapping channels with narrowings. The microchannel network is fused with the optical glass. In one aspect the device is used with a petri dish having an optical window. In another aspect the device is used with a well plate having a plurality of wells and associated optical windows. In a third aspect the device is used with a barrier. Each of the aspects forms a peripheral space around the optofluidic microdevice capable of retaining a live culture of biological targets and material that is desired to be injected into those biological targets. Polymer tubing is inserted into the central vertical outlet which connects the device to an external pump.Type: ApplicationFiled: April 18, 2014Publication date: November 6, 2014Inventor: David Fozdar
-
Publication number: 20140331357Abstract: The present invention discloses transgenic seeds for crops with enhanced agronomic traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more enhanced traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein.Type: ApplicationFiled: March 27, 2014Publication date: November 6, 2014Applicant: Monsanto Technology LLCInventor: Marie Coffin
-
Publication number: 20140302119Abstract: Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles containing interfering RNAs can stably, high efficiently and specifically deliver interfering RNAs, microvesicles containing interfering RNAs can be used to treat related diseases.Type: ApplicationFiled: May 26, 2010Publication date: October 9, 2014Applicant: Micromedmark Biotech Co. Ltd.Inventors: Chenyu Zhang, Ke Zeng, Danqing Liu, Yujing Zhang, Hongwei Gu
-
Publication number: 20140294935Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.Type: ApplicationFiled: May 12, 2014Publication date: October 2, 2014Inventors: Francois-Xavier Jacques Berthet, Wilfried Dalemans, Philippe Denoel, Guy Dequesne, Christiane Feron, Yves Lobet, Jan Poolman, George Thiry, Joelle Thonnard, Pierre Voet
-
Publication number: 20140294840Abstract: Provided are human miRNAs associated with the generation of immunological tolerance during pregnancy as well as fragments, derivatives and variants thereof for use in immunomodulation. Said miRNAs may be used in diagnosis and treatment of disorders associated with a deregulated immune response, autoimmune disorders, pregnancy associated diseases, failure or problems of placentation and complications resulting from allotransplantations. In addition, new pharmaceutical and diagnostic compositions for use in diagnosis and therapy of said disorders are described.Type: ApplicationFiled: November 30, 2012Publication date: October 2, 2014Inventors: Jorn Bullerdiek, Inga Flor
-
Publication number: 20140256771Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: October 19, 2012Publication date: September 11, 2014Inventors: Jianguo Cao, Jeffrey P. Whitten, Zhijun Wang, Evan Rogers, Jonathan Grey
-
Publication number: 20140242105Abstract: The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus Chlamydia. In particular, the present invention relates to isolated B- and T-cell epitopes derived from the major outer membrane protein of Chlamydia psittaci which can be used against an infection with a species of the genus Chlamydia. More in particular, the invention provides a vaccine which can be used against chlamydiosis caused by Chlamydia psittaci in birds and man. In addition, the invention relates to a diagnostic method to diagnose the latter infections.Type: ApplicationFiled: June 15, 2012Publication date: August 28, 2014Applicant: UNIVERSITEIT GENTInventor: Daisy Vanrompay
-
Publication number: 20140242640Abstract: The present invention is in the fields of nanotechnology and biomimetics. In particular, the present invention relates to the use of modified ribosomes to produce biomimetic structures. These biomimetic structures, also known as directed element polymers, are not produced by traditional industrial means but instead are produced by living systems comprising modified ribosomes.Type: ApplicationFiled: September 27, 2013Publication date: August 28, 2014Inventor: Alexander SUNGUROFF
-
Publication number: 20140234375Abstract: Provided herein are cells, vectors and viruses in association with a mutant polypeptide that has emerged in response to a therapeutic or prophylactic agent; compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response.Type: ApplicationFiled: December 17, 2013Publication date: August 21, 2014Applicant: Globelmmune, Inc.Inventors: David Apelian, Alex Franzusoff, Timothy C. Rodell
-
Patent number: RE46860Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.Type: GrantFiled: July 6, 2016Date of Patent: May 22, 2018Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
-
Patent number: RE46897Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.Type: GrantFiled: July 6, 2016Date of Patent: June 19, 2018Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner